<DOC>
	<DOC>NCT00745823</DOC>
	<brief_summary>A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve human immunodeficiency virus (HIV)-infected patients.</brief_summary>
	<brief_title>A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)</brief_title>
	<detailed_description>Following the 96-week double-blind study period (MK0518-071)(NCT00745823), subjects may enroll in an extension study (MK0518-071-10)(NCT00745823). From weeks 96 to 120, subjects' treatment assignments will remain as in the base study. From week 120 to 240, all subjects will receive open-label raltegravir (800 mg, once daily) in combination with TRUVADA™.</detailed_description>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient is male or female 18 years of age or older Patient is HIV positive Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART Extension Study: The planned extension study did not take place as the study was terminated after the Week 48 analysis. Patient is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence Patient has documented resistance to tenofovir or emtricitabine Patient is currently participating or has participated in a study with an investigational compound or device within 45 days of signing informed consent Patient is pregnant or breastfeeding, or expecting to conceive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Treatment Naïve</keyword>
</DOC>